About 30,000 people will take part in the critical phase of the race to get vaccinated against the virus • Volunteers will receive two doses of the vaccine that are supposed to provide immunity to the virus
Step 3 is underway
Photo:
IPA Archive
The clinical trial of the Modern Company is gaining momentum and entering today (Monday) the third phase during which 30,000 volunteers will receive doses of the vaccine developed by the Biotechnology Society and the National Institute of Infectious Diseases. The volunteers are scattered throughout the United States, and as reported by CNN, the first to receive was a resident of Savannah in the state of Georgia.
As reported, at this stage of the trial participants will receive 100 micrograms injections of the vaccine or alternatively placebo injections one month apart, with Modern arguing that the symptoms of the disease will disappear after receiving two doses.
According to the results of the first stages of the study in question, in the first part of the experiment it included a limited number of people and focused on the question of health hazard, then the study was extended to people with appropriate age characteristics and health status. At present, thousands of people will receive the vaccine and the effectiveness of reducing the symptoms and the safety of those who receive it will be tested.
According to the World Health Organization, Modern's trial is one of 25 trials worldwide. Yesterday, the company announced that it had received additional funding of $ 472 million from the US Research Authority, which raised the total amount invested in the development of the vaccine to $ 955 million.
